Initial Statement of Beneficial Ownership (3)
March 16 2020 - 5:42PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Wessel Thomas |
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/9/2020
|
3. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [RLMD]
|
(Last)
(First)
(Middle)
C/O RELMADA THERAPEUTICS, INC., 880 THIRD AVENUE, 12TH FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) EVP, Head of R&D / |
(Street)
NY, NY 10022
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Options to purchase common stock | 3/9/2020 (1) | 3/9/2030 | Common Stock | 350000 | $45.61 | D | |
Explanation of Responses: |
(1) | Options granted on March 9, 2020 to purchase an aggregate of 350,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Wessel Thomas C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NY, NY 10022 |
|
| EVP, Head of R&D |
|
Signatures
|
/s/ Thomas Wessel | | 3/16/2020 |
**Signature of Reporting Person | Date |
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Sep 2023 to Sep 2024